Physician Education: Bridging Clinical Research and Patient Care

Cases on the Web Editorial Board

Members of the COW Editorial Board participate in a volunteer capacity. They are not compensated for their role in overseeing the program. Listed below are the COW Editorial Board members and their financial interests with commercial companies within the past 12 months from the date of disclosure.

Michael S. Saag, MD — Editor in Chief
Professor of Medicine
University of Alabama at Birmingham

Dr Saag has received research grants and support awarded to his institution from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, Merck, and ViiV Healthcare. He has also served as a consultant for Bristol-Myers Squibb, Gilead Sciences, Inc, Merck, and Teva Pharmaceutical Industries, Ltd, and ViiV Healthcare. (Updated 02/21/17)

Marshall J. Glesby, MD, PhD — Coeditor
Professor of Medicine and Healthcare Policy and Research
Weill Cornell Medicine

Dr Glesby has received research support, paid to his institution, from Gilead Sciences, Inc (pending as of February 2017). (Updated 02/20/17)

Judith A. Aberg, MD
Chief of the Division of Infectious Diseases
Icahn School of Medicine at Mount Sinai

Dr Aberg serves as a scientific advisor to Merck and has received research support, paid to her institution, from Bristol-Myers Squibb and Gilead Sciences, Inc.  (Updated 02/17/17)

Roger J. Bedimo, MD, MS, FACP
Associate Professor of Medicine
University of Texas Southwestern Medical Center

Dr Bedimo has received grants and research support awarded to the Veterans Affairs North Texas Healthcare System from Merck. He has served as a scientific advisor for Bristol-Myers Squibb, Merck, and Theratechnologies, Inc. (Updated 02/20/17)

Kara W. Chew, MD
Assistant Clinical Professor of Medicine
University of California Los Angeles

Dr Chew has received research support awarded to the University of California Los Angeles from Gilead Sciences, Inc, and Merck. (Updated 02/16/17)

Paul E. Sax, MD
Professor of Medicine
Harvard Medical School

Dr Sax has served as a consultant or advisor to AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline/ViiV, Janssen Therapeutics, and Merck. He has received grant support, paid to his institution, from Bristol-Myers Squibb, Gilead Sciences, Inc, and GlaxoSmithKline/ViiV. (Updated 02/17/17)

Steven C. Johnson, MD
Professor of Medicine, Division of Infectious Diseases
University of Colorado School of Medicine

Dr Johnson has no relevant financial affiliations to disclose. (Updated 12/1/16)

Harry W. Lampiris, MD
Professor of Clinical Medicine
University of California San Francisco

Dr Lampiris has no relevant financial affiliations to disclose. (Updated 02/17/17)

David L. Wyles, MD
Associate Professor of Medicine
University of California San Diego

Dr Wyles has received research grants awarded to his institution from AbbVie, Gilead Sciences, Inc, Merck, and Tacere Therapeutics, Inc. He has also served as a consultant for AbbVie, Gilead Sciences, Inc, and Merck. (Updated 02/16/17)

Emily J. Cartwright, MD — Fellow Editor
Fellow in Infectious Diseases
Emory University

Dr Cartwright has received research grants awarded to Emory University from Bristol-Myers Squibb and Gilead Sciences, Inc. (Updated 02/16/17)

Staff of the Cases on the Web

Donna M. Jacobsen — Executive Director/President
Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 02/16/17)

IAS–USA Board of Directors

The nonstaff members of the IAS–USA Board of Directors participate in a volunteer capacity. They are not compensated for their roles in governing/overseeing the IAS–USA. Listed below are the IAS–USA Board of Directors and their financial interests with commercial companies within the last 12 months from the date of disclosure.

Constance A. Benson, MD
Professor of Medicine
University of California San Diego

Dr Benson serves on a data and safety monitoring board for GlaxoSmithKline/ViiV Healthcare. She has received research grants awarded to her institution from AbbVie, Gilead Sciences, Inc, and ViiV Healthcare. Information for her spouse, Dr Robert T. Schooley, is included below. (Updated 01/20/17) 

Judith S. Currier, MD
Professor of Medicine
University of California Los Angeles

Dr Currier has no relevant financial affiliations to disclose. (Updated 01/19/17)

Carlos del Rio, MD
Professor of Global Health
Emory University

Dr del Rio has served as a consultant for InnaVirVax. (Updated 01/17/17)

Joel E. Gallant, MD, MPH
Adjunct Professor of Medicine
The Johns Hopkins University

Clinical Professor of Medicine
University of New Mexico School of Medicine

Dr Gallant has served as a consultant or advisor to Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, Merck, and ViiV Healthcare/GlaxoSmithKline. He has received research grants or contracts awarded to his institution from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, Inc, Merck, Sangamo BioSciences, and ViiV Healthcare/GlaxoSmithKline. (Updated 01/19/17)

Roy M. Gulick, MD, MPH
Rochelle Belfer Professor in Medicine
Weill Cornell Medicine

Dr Gulick has no relevant financial affiliations to disclose. (Updated 01/31/17)

Jeanne M. Marrazzo, MD, MPH, FACP, FIDSA
Professor of Medicine
University of Alabama at Birmingham
Dr Marrazzo has no relevant financial affiliations to disclose. (Updated 01/19/17)

Douglas D. Richman, MD
Professor of Pathology and Medicine
University of California San Diego

Dr Richman has been a consultant to Antiva Biosciences, Chimerix, Gilead Sciences, Inc, and Monogram Biosciences, Inc. (Updated 01/20/17)

Michael S. Saag, MD
Professor of Medicine
University of Alabama at Birmingham

Dr Saag has received research grants and support awarded to his institution from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, Merck, and ViiV Healthcare. He has also served as a consultant for Bristol-Myers Squibb, Gilead Sciences, Inc, Merck, and Teva Pharmaceutical Industries, Ltd, and ViiV Healthcare. (Updated 02/21/17)

Robert T. Schooley, MD
Professor and Vice Chair of Medicine
University of California San Diego

Dr Schooley was awarded research grants, paid to his institution, from AbbVie, Bristol-Myers Squibb, and Merck. His institution has received payment for his consultative advice or data monitoring committee service from Gilead Sciences, Inc, GlobeImmune, and Monogram Biosciences. He serves as a consultant to Antiva Biosciences, CytoDyn, and Farmak. He has stock options from Antiva Biosciences and CytoDyn. (Updated 1/19/17)

Paul A. Volberding, MD
Professor of Medicine
University of California San Francisco

Dr Volberding has served on data and safety monitoring boards for Merck. (Updated 02/13/17)